Table of Content

08 April 2016, Volume 43 Issue 4 Previous Issue    Next Issue

For Selected:

Download Citations EndNote Reference Manager ProCite BibTeX RefWorks

Toggle Thumbnails

Effects of curcumin combined with cisplatin on growth and lymphatic metastasis of cervical cancer xenografts in nude mice LIU Dong-Ju, ZHAO Qiu-Sheng, YAO Yu 2016, 43 (4):  241-245.  doi: 10.3760/cma.j.issn.1673422X.2016.04.001 Abstract ( 303 )   PDF (933KB) ( 1185 )   Save ObjectiveTo analyze the effects of curcumin combined with cisplatin on the growth and lymphatic metastasis of cervical cancer xenografts in nude mice. MethodsThe human cervical carcinoma Caski cells xenotransplanted tumor models were established. Inoculated mice were randomly divided into 4 groups according to random number table: control (normal saline 10 ml/kg), Cur (curcumin 100 mg/kg), Cis (cisplatin 3 mg/kg) and Cur＋Cis group (100 mg/kg curcumin＋3 mg/kg cisplatin). The tumor volume and antitumor rate were calculated． The mRNA levels of macrophage migration inhibitory factor (MIF) and vascular endothelial growth factorC (VEGFC) were analyzed by realtime fluorescent quantitative polymerase chain reaction (PCR). ResultsThe inhibitory rates of Cur group, Cis group and Cur＋Cis group were 40.8%, 53.3% and 60.0%. After 15 days treatment, the tumor volumes of the control group, Cur group, Cis group and Cur＋Cis group were (123.44±35.62), (71.72±28.36), (65.47±18.32), (53.44±10.79)mm3. The growth rates of tumor volume in Cur group, Cis group and  Cur＋Cis group were slower, Cur＋Cis group could more effectively inhibit tumor volume growth. The difference among the four groups had statistically significance (F=16.890, P=0.000). Realtime fluorescent quantitative PCR detection showed that compared with the control group (1.000), the MIF mRNA expressions in Cur group, Cis group and Cur＋Cis group were 0.322±0.094, 0.154±0.006 and 0.136±0.007, VEGFC mRNA expressions in the three groups were 0.312±0.068, 0.263±0.072 and 0.221±0.041. The differences among groups had statistically significance (F=220.279, P=0.000; F=143.250, P=0.000). MIF mRNA was positively related with VEGFC mRNA (r=0.815, P=0.001). ConclusionCurcumin combined with cisplatin can inhibit the growth of Carski cell xenografts in nude mice. Through the downregulating expression of MIF mRNA and VEGFC mRNA, cisplatin and curcumin can inhibit the lymphatic metastasis of cervical cancer, and it may be one of the important mechanisms of its antitumor effects. Related Articles | Metrics

The expression of ZNRF3 in thyroid cancer and its functions in thyroid cells QIU Wang-Wang, YANG Zhi-Li, YAN Jun, YU Song, ZHENG Qi 2016, 43 (4):  246-249.  doi: 10.3760/cma.j.issn.1673422X.2016.04.002 Abstract ( 400 )   PDF (1014KB) ( 1119 )   Save ObjectiveTo detect the expression and function of ZNRF3 in different kinds of thyroid cancer tissues and cells. MethodsImmunohistochemistry was used to detect the expressions of ZNRF3 protein in 35 cases of papillary thyroid carcinoma and 10 cases of poorly differentiated thyroid carcinoma. The expressions of ZNRF3 gene in TPC1 and 8505C were detected by RTPCR, and the cell lines were derived from papillary thyroid carcinoma and poorly differentiated thyroid carcinoma respectively. After silenced ZNRF3 gene expression with lentivirus, the proliferation ability of TPC1 cells were detected with CCK8, the invasion and metastasis ability of TPC1 cells were detected with Transwell. ResultsAccording to results of immunohistochemistry and RTPCR, the expressions of ZNRF3 in papillary thyroid carcinoma cells and tissues were higher than those in poorly differentiated thyroid carcinoma cells and tissues, the differences were statistically significant (4.83±0.44 vs.3.13±0.59, t=2.20, P<0.05; 1.01±0.06 vs.0.21±0.04, t=11.80, P<0.01). After ZNRF3 geng silencing, according to the results of CCK8, the proliferation ability of TPC1 cells was significantly enhanced in 72 h, the difference was statistically significant (0.96±0.10 vs.0.64±0.05, t=3.19, P<0.05); and according to the results of Transwell, the TPC1 cell′s invasion (0.12±0.01 vs.0.09±0.00, t=5.48, P<0.01) and migration (0.22±0.01 vs.0.17±0.01, t=4.58, P<0.05) also increased, the differences were statistically significant. ConclusionThe expression of ZNRF3 in papillary thyroid carcinoma is higher than that in poorly differentiated thyroid cancer. ZNRF3 is tumor suppressor gene in the thyroid tumors. Related Articles | Metrics

The clinical and pathological characteristics of breast cancer in women ≤40 years of age XU Hu, ZHANG Fang, KOU De-Qiang, WANG Jian-Dong 2016, 43 (4):  250-253.  doi: 10.3760/cma.j.issn.1673422X.2016.04.003 Abstract ( 424 )   PDF (684KB) ( 1196 )   Save ObjectiveTo retrospectively analyze the clinical and pathological characteristics of breast cancer in women ≤40 years of age. MethodsOne hundred and thirty one young (≤40 years) female patients with breast cancer pathologically confirmed in the General Hospital of PLA from January 1st 2008 to December 31st 2012 (young group) were collected, and 262 elderly (4169 years) female patients with breast cancer in the same period (old group) were collected as control using the random number table method. The clinicopathological characteristics involved TNM staging, histological grade, the expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor2 (Her2) and clinical stage of the two groups were contrastively analyzed. ResultsCompared with elderly patients, young female patients with breast cancer had lower positive rate of ER or PR (64.9% vs. 76.7%; χ2=6.171, P=0.013), higher positive rate of Her2 (26.7% vs. 15.3%; χ2=7.415, P=0.006) and higher histological grade (grade Ⅱ 38.2% vs. 35.1%; grade Ⅲ 55.7% vs. 49.6%; χ2=6.835, P=0.033). There were no significant differences in T stage (χ2=1.764, P=0.623), N stage (χ2=0.129, P=0.988), clinical stage (χ2=4.916, P=0.178), molecular subtype (χ2=7.475, P=0.058) and different surgical procedures (χ2=0.913, P=0.339) between the two groups. ConclusionYoung (≤40 years) female patients with breast cancer have specific clinical and pathological characteristics including higher histological grade, higher positive rate of Her2, lower positive rate of ER or PR and higher degree of malignancy, who should be diagnosed and treated as soon as possible. Related Articles | Metrics

Prognostic factors of relapse and metastasis after radical resection of lung adenocarcinoma ZHANG Ya-Fei, LIU Pan, ZHAO Hua-Rong, WANG Shan-Shan, SUN Rui-Rui 2016, 43 (4):  254-257.  doi: 10.3760/cma.j.issn.1673422X.2016.04.004 Abstract ( 572 )   PDF (752KB) ( 3183 )   Save ObjectiveTo explore the risk factors of local relapse and distant metastasis after radical resection of lung adenocarcinoma. MethodsA total of 102 patients with lung adenocarcinoma operated in First Affiliated Hospital of Xinjiang Medical University from January 2005 to January 2010 were collected．The correlation between clinicopathological characteristics and prognosis was evaluated by singlefactor and multifactor analyses. The survival curves were plotted using KaplanMeier. Singlefactor analysis of statistical difference was tested using Logrank test. Multifactor analysis of prognostic factors were produced by COX regression proportional hazards model. ResultsIn the whole group, 1, 2, 3 and 5 year diseasefree survival rates were 74.30%, 58.00%, 51.50% and 44.90% respectively, and the median diseasefree survival was 30 months. Singlefactor analysis showed that tumor size (χ2=9.951, P=0.002), clinical type (χ2=8.460, P=0.004), differentiated degree (χ2=4.807, P=0.028), lymph node metastasis (χ2=40.516, P=0.000), pathological stage (χ2=38.769, P=0.000) were prognostic factors for local relapse and distant metastasis in postoperative patients with lung adenocarcinoma. Mutifactor analysis showed that tumor size (OR=1.943, 95%CI: 1.0913.463, χ2=5.082, P=0.024), differentiated degree (OR=2.570, 95%CI: 1.4514.552, χ2=10.467, P=0.001), lymph node metastasis (OR=3.196, 95%CI: 1.0379.849, χ2=4.096, P=0.043) were independent prognostic factors for local relapse and distant metastasis in postoperative patients with lung adenocarcinoma. ConclusionTumor size, differentiated degree and lymph node metastasis are independent prognostic factors for local relapse and distant metastasis in postoperative patients with lung adenocarcinoma. Related Articles | Metrics

Clinical research of microwave ablation plus sorafenib in the treatment of advancedstage hepatocellular carcinoma ZHANG Ya-Fei, SHENG Li-Jun, SUN Ya-Hong, SONG Peng-Yuan, REN Guo-Hua, AN Yu-Ji- 2016, 43 (4):  258-261.  doi: 10.3760/cma.j.issn.1673422X.2016.04.005 Abstract ( 380 )   PDF (912KB) ( 996 )   Save ObjectiveTo compare the clinical effects and adverse effects of microwave ablation (MWA) with sorafenib and sorafenib monotherapy in the treatment of advancedstage hepatocellular carcinoma (HCC). MethodsMedical records and followup information of 57 patients with advancedstage HCC were retrospectively reviewed. 25 patients were treated with MWA combined with sorafenib (combined group), and 32 patients were treated with sorafenib monotherapy (monotherapy group). The end points were therapeutic effect, progressionfree survival (PFS), overall survival (OS) and adverse reactions. ResultsThe objective response rate in the combined group was similar to the monotherapy group (16.0% vs. 3.1%, χ2=1.521, P=0.217). The disease control rate in the combined group was significantly higher than that in the monotherapy group (80.0% vs. 50.0%, χ2=5.429, P=0.020). The median PFS in the combined group was longer than that in the monotherapy group (6.0 months vs. 3.2 months, χ2=7.675, P=0.006), but the median OS was similar (11.5 months vs. 8.5 months, χ2=2.480, P=0.115). The serious adverse reactions were similar between the two treatment groups (44.0% vs. 34.4%, χ2=0.549, P=0.459). ConclusionMWA plus sorafenib is superior to sorafenib alone with respect to PFS in patients with advancedstage HCC, although it may not improve OS, with no increased risk of serious adverse reactions. Related Articles | Metrics

Analysis of prognostic factors and different treatment modalities for patients with early cervical squamous cell carcinoma after surgery in Xinjiang ZHANG Lei, SUN Rui-Rui, ZHAO Hua-Rong, HU 尔Xi-Dan-·Ni-Ya-Zi, ZHANG Song-An, RE He-Man-·Yi-Ming, ZHANG Ya-Fei, WANG Shan-Shan 2016, 43 (4):  262-266.  doi: 10.3760/cma.j.issn.1673422X.2016.04.006 Abstract ( 434 )   PDF (691KB) ( 803 )   Save ObjectiveTo explore prognostic factors and different treatment modalities efficacy for patients with early cervical squamous cell carcinoma postoperative. MethodsThe clinical pathologic parameters in 130 inpatients of cervical squamous cell carcinoma after surgical were retrospectively analyzed. The patients were followed up for 5 years. The survival rate was calculated by KaplanMeier method and the difference was compared by Logrank test. Multivariate analysis was performed using Cox regression model. ResultsUnivariate analysis showed that parity（χ2=7.378, P=0.007), Federation International of Gynecology and Obstetrics (FIGO) stage (χ2=4.124, P=0.042), tumor size (χ2=4.070, P=0.044), lymph node metastasis (χ2=11.936, P=0.001), treatment approach (χ2=8.523, P=0.014), serum level of squamous cell carcinoma antigen (SCCA) (χ2=6.399, P=0.011）and platelet and lymphocyte ratio (PLR) (χ2=5.588, P=0.018) impact on the 5year survival rate. Multivariate analysis showed that parity (OR=4.379, 95%CI: 1.49212.854, χ2=7.226, P=0.007), FIGO stage (OR=4.129, 95%CI: 1.40112.168, χ2=7.827, P=0.005), lymph node metastasis (OR=7.312, 95%CI: 2.61720.430, χ2=14.819, P=0.000), treatment approach (OR=0.242, 95%CI: 0.0820.713, χ2=6.662, P=0.010) and PLR (OR=5.375, 95%CI: 1.35121.375, χ2=5.862, P=0.017) were independent prognostic factors for cervical squamous cell carcinoma patients. In 106 cases of patients with risk factors of cervical squamous cell carcinoma, patients who having surgery alone, surgery plus radiotherapy, surgery plus chemoradiotherapy had 5year survival rates of 61.8%, 83.3% and 90.4%, respectively, and the difference was statistical significant (χ2=8.467, P=0.014). ConclusionParity, FIGO stage, lymph node metastasis, treatment approach and PLR are independent prognostic factors in patients with early cervical squamous cell carcinoma. Adjuvant therapy is recommended in cervical cancer patients with risk factors after operation,  it can improve patients′ survival rates and quality of life. Related Articles | Metrics

Expression and clinical significance of microRNA7 in serum of ovarian cancer patients JIAO Li-Min, LIANG Jin, WANG Qiong, LI Ji-Qiang 2016, 43 (4):  267-270.  doi: 10.3760/cma.j.issn.1673-422X.2016.04.007 Abstract ( 318 )   PDF (768KB) ( 1024 )   Save ObjectiveTo explore the expression and clinical significance of microRNA7 (miR7) in serum of ovarian cancer patients. MethodsSerum samples of 42 ovarian patients confirmed by pathological histology and 40 healthy women who underwent a physical exam were collected from January 2011 to January 2012 in the Sixth People′s Hospital of Foshan Nanhai District of Guangdong Province. Expression levels of miR7 in the serum samples of the two groups were examined using reverse transcriptionreal time polymerase chain reaction (RTPCR). The relationship between the expression of miR7 and the clinicopathologic feature of ovarian was analyzed. ResultsCompared with the controls, the expression of miR7 in the serum of ovarian cancer patients was significantly reduced (0.246±0.017 vs. 0.488±0.042), with a significant difference (t=11.23, P=0.01). The expression of miR7 in the serum of ovarian cancer patients was related to the clinical stage (t=10.12, P=0.01), pathological type (t=6.90, P=0.02), differentiation degree (t=4.46, P=0.03), regional lymph node or distant metastasis (t=5.62, P=0.02), but it was not related to the age (t=0.03, P=0.83). The patients with high miR7 expression had better overall survival than the patients with low miR7 expression (36.7 months vs. 24.3 months), with a significant difference (χ2=6.04, P=0.02). ConclusionThe expression of miR7 in serum of ovarian cancer patients is down regulated, which may be helpful for the overall assessment of ovarian carcinoma. miR7 may be one of the important prognostic indicators for ovarian carcinoma. Related Articles | Metrics

SOX7 and its expression and function in tumors HE Hui-Ping, XU Zu-Min, GUAN Cheng-Nong 2016, 43 (4):  271-273.  doi: 10.3760/cma.j.issn.1673422X.2016.04.008 Abstract ( 603 )   PDF (672KB) ( 1047 )   Save SOX7 belongs to the SOX gene family. And it has been shown to regulate multiple biological processes. Studies have found that SOX7 gene is likely to be a tumor suppressor gene. In many tumors, SOX7 downregulation that inhibits proliferation, migration and invation of tumor via regulating the Wntβcatenin signaling pathway mediated the transcription process, which plays a significant role in tumorigenesis. Related Articles | Metrics

Mechanisms of FOXM1 in carcinogenesis and the progression of the antiFOXM1 target drugs TIAN Chuan, LI Qi 2016, 43 (4):  274-277.  doi: 10.3760/cma.j.issn.1673422X.2016.04.009 Abstract ( 642 )   PDF (682KB) ( 1063 )   Save Forkhead box M1 (FOXM1)， one member of the Forkhead family， plays an important role in tumor development, invasion, metastasis and angiogenesis by regulating the expression of tumor related genes. Moreover, The specific mechanism of FOXM1 is not fully understood in the development of tumors. Currently，the study of anticancer drugs targeting FOXM1 is in the initial stage. Exploring the mechanism of FOXM1 in carcinogenesis and the development of drugs targeting FOXM1 and its downstream signaling pathways have broad clinical application prospects. Related Articles | Metrics

Research progression about the HMGN protein in tumor LIU Bei-Li, WAN Yi-Xin 2016, 43 (4):  278-281.  doi: 10.3760/cma.j.issn.1673422X.2016.04.010 Abstract ( 378 )   PDF (678KB) ( 1068 )   Save High mobility group N (HMGN), one member of the high mobility group superfamily, is expressed ubiquitously in living cells. HMGN can bind directly to nucleosomes and modulate the structure of the chromatin fiber, which affect the cellular transcription profile and cellular differentiation and the ability to repair damaged DNA. The occurence of tumor is closely related to the abnormal transcription caused by accumulation of mutations. Abnormal transcription can prompt the tumor cells to escape from the tight regulation of cell cycle progression. Studies show that HMGN plays an important role in cancer progression by involving in the regulation of tumor cell cycle and affecting the biological behavior of tumor cells. Related Articles | Metrics

Relationship between fibrinogen and tumor and the mechanism LI Ying, LI Da-Wei, YU Yang-Li, JIAO Wei, YAN Lei, LIU Hai-nan, XU Zhong-Hua 2016, 43 (4):  282-284.  doi: 10.3760/cma.j.issn.1673422X.2016.04.011 Abstract ( 927 )   PDF (671KB) ( 1787 )   Save Fibrinogen (Fib) is one of the most common coagulation proteins, plays an important role in the coagulation cascade, and has a closed relationship with tumor. Studies indicate that the level of Fib has elevated in many kinds of cancer, and Fib is also closely correlated with the progression, metastasis and prognosis of tumor. Though the mechanism of the interaction of Fib and tumor is still unclear, Fib as a tumor marker and new therapy for these malignancies has been a new hotspot. Related Articles | Metrics

3Phosphoinositidedependent protein kinase1 in tumor genesis, development and treatment LIU Tian-Tian, BI Jing-Wang 2016, 43 (4):  285-288.  doi: 10.3760/cma.j.issn.1673422X.2016.04.012 Abstract ( 504 )   PDF (737KB) ( 1191 )   Save 3phosphoinositide dependent kinase1 (PDK1) has been shown to be a critical regulator of the PI3KAkt pathway. PDK1 can activate Akt and participates in the activation of PI3KAkt signaling pathway to promote tumor development, invasion and metastasis. At present, it has been found that PDK1 is highly expressed in head and neck cancer, multiple myeloma, pancreatic cancer, esophageal cancer, colon cancer and other malignant tumors. Thereby inhibiting PDK1 overexpression may provide a new breakthrough for the treatment of malignant tumor. At present, many kinds of PDK1 inhibitors have been put into production, which plays an important role in tumor therapy. Related Articles | Metrics

Receptor of activated Ckinase 1 and solid tumors TIAN Guang-Wei, LI Nan, XIN Yan 2016, 43 (4):  289-292.  doi: 10.3760/cma.j.issn.1673422X.2016.04.013 Abstract ( 350 )   PDF (681KB) ( 1159 )   Save Receptor of activated Ckinase 1 (RACK1) shows different expression in various tumors, because its seven WD repeating sequences can combine with a variety of molecules. In addition to activating protein kinases C, RACK1 still plays a role in many tumorrelated signaling pathways. With the deepening of research, RACK1 is expected to play an active role in cancer diagnosis, treatment and prognosis. Related Articles | Metrics

Antitumor mechanism of gambogic acid ZHANG Wen-Dian, XU Zu-Min, YU Zhong-Hua 2016, 43 (4):  293-295.  doi: 10.3760/cma.j.issn.1673422X.2016.04.014 Abstract ( 686 )   PDF (670KB) ( 1588 )   Save It is found that gambogic acid can play antitumor effects through different mechanisms in a variety of tumor cells, including induce apoptosis, inhibit telomerase and topoisomerase activity, inhibit the expression of heat shock protein and channel protein, inhibit tumor angiogenesis and metastasis and reverse multidrug resistance. Gambogic acid is expected to become a new antitumor drug, still need to be further explored its value in the field of antitumor. Related Articles | Metrics

Application of agents of antiPD-L1 antibody in advanced tumor therapy JING Qiong-You, PU Da-Xun, JIANG Tao, HUANG Yu-Hang, WANG Jian-Bing, LI Shi-Qiang 2016, 43 (4):  296-298.  doi: 10.3760/cma.j.issn.1673422X.2016.04.015 Abstract ( 295 )   PDF (674KB) ( 1355 )   Save Programmed death1 (PD1) and its ligand 1 (PDL1) play critical roles in the identification and elimination of tumor cells evading the host′s immune system. Tumor model in mice which is given antiPDL1 monoclonal antibody shows obviously host antitumor response. Currently, immunotherapy drugs of PD1/PDL1 signaling pathways receive good effects in a variety of tumors failure of the traditional method, and with less adverse reaction, which provide valuable clinical experiences in advanced tumor immunotherapy. Related Articles | Metrics

Semaphorin familily and glioma ZHANG Hai-Dong, ZHANG Wei, WANG Hui, ZHU Guang-Ting 2016, 43 (4):  299-301.  doi: 10.3760/cma.j.issn.1673422X.2016.04.016 Abstract ( 277 )   PDF (674KB) ( 1192 )   Save Semaphorins act as axon guidance molecules, which were either secretory or binding to the cell surface. All its family members contain a Sema structure, which is composed of about 500 amino acid residues and is essential for its biological activity. Functionally, they play different roles in tumors, such as oncogenes or tumor suppressor genes, and their abnormal expressions are related to the proliferation, migration and invasion of glioma cells. Semaphorins may be the therapeutic targets for the clinical treatment of glioma. Related Articles | Metrics

The diagnosis and treatment of breast ductal carcinoma in situ CHEN Chuan-Zhi, MA Rui-Min, GUO Gui-Long 2016, 43 (4):  302-305.  doi: 10.3760/cma.j.issn.1673422X.2016.04.017 Abstract ( 334 )   PDF (682KB) ( 1469 )   Save Accurate knowledge, diagnosis and treatment of breast ductal carcinoma in situ(DCIS), are crucial in controlling the development of breast cancer. In the diagnosis phase, breast ultrasound is commonly used as a screening tool, and a clear diagnosis can be made by mammography. Meanwhile, serological tests contribute to the detection of DCIS in early stages. In the treatment, the optimal surgical operation method remains debatable. It is widely acknowledged that the radiotherapy of postoperative patients should become more individualized. In addition, corresponding endocrine therapy helps those ER positive patients to reduce the recurrence. In the development of DCIS to invasive cancer, there are changes in gene and protein expressions, which may be a potential direction for further research. Related Articles | Metrics

Advances in the comprehensive treatment of young women patients with breast cancer ZHANG Wen-Long, ZHANG Jian-Hua 2016, 43 (4):  306-308.  doi: 10.3760/cma.j.issn.1673422X.2016.04.018 Abstract ( 260 )   PDF (668KB) ( 1094 )   Save The incidence rate of young women with breast cancer is increasing. Because of distinct biological characteristics of breast cancer in young patients, it is reasonable to identify who is the best one for breastconserving surgery. Patients with systemic chemotherapy should be fully considered about fertility requirements. In addition, endocrine therapy combined with ovarian function inhibition can improve the effect, meanwhile, there should increase the proportion of patients with targeted therapy. Related Articles | Metrics

Targeted therapy of breast cancer ZHANG Cheng, ZHANG Zheng-Quan, FU De-Yuan 2016, 43 (4):  309-311.  doi: 10.3760/cma.j.issn.1673422X.2016.04.019 Abstract ( 416 )   PDF (673KB) ( 1269 )   Save Targeted therapies of breast cancer offer a possibility of effective and individualized therapy based on the molecular profile of the tumor. Currently there are three main types of targeted therapeutic drugs for breast cancer, the first category is the monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) including trastuzumab, pertuzumab, lapatinib, TDM1. The second is targeting VEGF such as bevacizumab. The last one everolimus is a mammalian target of rapamycin (mTOR) inhibitors. A number of trials suggest that the addition of targeted therapy to chemotherapy or endocrine therapy significantly improved PFS and OS in patients with breast cancer. Related Articles | Metrics

Application of EGFR-TKI in locally advanced nonsmall cell lung cancer WU Xia, FENG Guo-Sheng 2016, 43 (4):  312-314.  doi: 10.3760/cma.j.issn.1673422X.2016.04.020 Abstract ( 319 )   PDF (675KB) ( 1410 )   Save With the deepening of the lung cancer molecular biology research, small molecular targets antitumor drugs make breakthrough progress, the epidermal growth factor receptor tyrosine kinase inhibitor (EGFRTKI) is one of the most attention drug. A series studies show that EGFRTKI can enhance the antitumor activity of ionizing radiation. Therefore, EGFRTKI combined with radiotherapy alone for poorrisk patients appears survival benefit, but can′t ignore the lung toxicity. However, there is a big controversy that EGFRTKI combined with chemoradiotherapy for locally advanced NSCLC. Related Articles | Metrics

Systemic inflammatory response and the prognosis of esophageal cancer ZHAO Si-Jun, LIU Di-Tian, CHEN Yu-Ping 2016, 43 (4):  315-318.  doi: 10.3760/cma.j.issn.1673422X.2016.04.021 Abstract ( 384 )   PDF (680KB) ( 1426 )   Save Systemic inflammatory response has a major role in the development and progression of cancer, and increased systemic inflammatory response usually correlates with poorer survival. Recently the evaluation index of systemic inflammatory response including neutrophillymphocyte ratio, Creactive protein, glasgow prognostic score,  plateletlymphocyte ratio. Several previous studies show that these indexes are the independent prognostic factors for esophageal cancer. Research on the systemic inflammatory markers may also be valuable for the clinical treatment and prognosis of esophageal cancer. Related Articles | Metrics